Haemophilia

Last updated

Haemophilia
Other names Hemophilia
PBB Protein F8 image.jpg
A drawing of clotting factor VIII
Pronunciation
Specialty Haematology
Symptoms Easy and prolonged bleeding [1]
Usual onsetAt birth [2]
CausesUsually genetic [3]
Diagnostic method Blood test [4]
Prevention Preimplantation screening [4]
TreatmentReplace missing blood clotting factors [3]
Frequency1 in 7,500 males (haemophilia A), 1 in 40,000 males (haemophilia B) [2] [5]

Haemophilia, or hemophilia [6] (from Ancient Greek αἷμα (haîma) 'blood',and φιλία (philía) 'love of'), [7] is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. [2] [3] This results in people bleeding for a longer time after an injury, easy bruising, and an increased risk of bleeding inside joints or the brain. [1] Those with a mild case of the disease may have symptoms only after an accident or during surgery. [1] Bleeding into a joint can result in permanent damage while bleeding in the brain can result in long term headaches, seizures, or a altered level of consciousness. [1]

Contents

There are two main types of haemophilia: haemophilia A, which occurs due to low amounts of clotting factor VIII, and haemophilia B, which occurs due to low levels of clotting factor IX. [2] They are typically inherited from one's parents through an X chromosome carrying a nonfunctional gene. [8] Most commonly found in men, haemophilia can affect women too, though very rarely. A woman would need to inherit two affected X chromosomes to be affected, whereas a man would only need one X chromosome affected. It is possible for a new mutation to occur during early development, or haemophilia may develop later in life due to antibodies forming against a clotting factor. [2] [8] Other types include haemophilia C, which occurs due to low levels of factor XI, Von Willebrand disease, which occurs due to low levels of a substance called von Willebrand factor, and parahaemophilia, which occurs due to low levels of factor V. [9] [10] Haemophilia A, B, and C prevent the intrinsic pathway from functioning properly; this clotting pathway is necessary when there is damage to the endothelium of a blood vessel. [11] [12] [13] Acquired haemophilia is associated with cancers, autoimmune disorders, and pregnancy. [14] [15] Diagnosis is by testing the blood for its ability to clot and its levels of clotting factors. [4]

Prevention may occur by removing an egg, fertilising it, and testing the embryo before transferring it to the uterus. [4] Human embryos in research can be regarded as the technical object/process. Missing blood clotting factors are replaced to treat haemophilia. [3] This may be done on a regular basis or during bleeding episodes. [3] Replacement may take place at home or in hospital. [16] The clotting factors are made either from human blood or by recombinant methods. [16] Up to 20% of people develop antibodies to the clotting factors which makes treatment more difficult. [3] The medication desmopressin may be used in those with mild haemophilia A. [16] Studies of gene therapy are in early human trials. [17]

Haemophilia A affects about 1 in 5,000–10,000, while haemophilia B affects about 1 in 40,000 males at birth. [2] [5] As haemophilia A and B are both X-linked recessive disorders, females are rarely severely affected. [8] Some females with a nonfunctional gene on one of the X chromosomes may be mildly symptomatic. [8] Haemophilia C occurs equally in both sexes and is mostly found in Ashkenazi Jews. [5] In the 1800s haemophilia B was common within the royal families of Europe. [5] The difference between haemophilia A and B was determined in 1952. [5]

Signs and symptoms

An illustration of a woman with hemophilia A woman suffering from Hemophilia.png
An illustration of a woman with hemophilia

Characteristic symptoms vary with severity. In general symptoms are internal or external bleeding episodes, which are called "bleeds". [18] [19] People with more severe haemophilia experience more severe and more frequent bleeds, while people with mild haemophilia usually experience more minor symptoms except after surgery or serious trauma. In cases of moderate haemophilia symptoms are variable which manifest along a spectrum between severe and mild forms. [20]

In both haemophilia A and B, there is spontaneous bleeding but a normal bleeding time, normal prothrombin time, normal thrombin time, but prolonged partial thromboplastin time. Internal bleeding is common in people with severe haemophilia and some individuals with moderate haemophilia. The most characteristic type of internal bleed is a joint bleed where blood enters into the joint spaces. [21] This is most common with severe haemophiliacs and can occur spontaneously (without evident trauma). If not treated promptly, joint bleeds can lead to permanent joint damage and disfigurement. [21] Bleeding into soft tissues such as muscles and subcutaneous tissues is less severe but can lead to damage and requires treatment. [22] Children with mild to moderate haemophilia may not have any signs or symptoms at birth, especially if they do not undergo circumcision. Their first symptoms are often frequent and large bruises and haematomas from frequent bumps and falls as they learn to walk. Swelling and bruising from bleeding in the joints, soft tissue, and muscles may also occur. Children with mild haemophilia may not have noticeable symptoms for many years. Often, the first sign in very mild haemophiliacs is heavy bleeding from a dental procedure, an accident, or surgery. Females who are carriers usually have enough clotting factors from their one normal gene to prevent serious bleeding problems, though some may present as mild haemophiliacs.[ citation needed ]

Complications

Severe complications are much more common in cases of severe and moderate haemophilia. Complications may arise from the disease itself or from its treatment: [23]

Haemophilic arthropathy is characterised by chronic proliferative synovitis and cartilage destruction. [24] If an intra-articular bleed is not drained early, it may cause apoptosis of chondrocytes and affect the synthesis of proteoglycans. The hypertrophied and fragile synovial lining while attempting to eliminate excessive blood may be more likely to easily rebleed, leading to a vicious cycle of hemarthrosis-synovitis-hemarthrosis. In addition, iron deposition in the synovium may induce an inflammatory response activating the immune system and stimulating angiogenesis, resulting in cartilage and bone destruction. [25]

Genetics

X-linked recessive inheritance X-linked recessive (2).svg
X-linked recessive inheritance

Typically, females possess two X-chromosomes, and males have one X and one Y-chromosome. Since the mutations causing the disease are X-linked recessive, a female carrying the defect on one of her X-chromosomes may not be affected by it, as the equivalent dominant allele on her other chromosome should express itself to produce the necessary clotting factors, due to X inactivation. Therefore, heterozygous females are just carriers of this genetic disposition. However, the Y-chromosome in the male has no gene for factors VIII or IX. If the genes responsible for production of factor VIII or factor IX present on a male's X-chromosome are deficient there is no equivalent on the Y-chromosome to cancel it out, so the deficient gene is not masked and the disorder will develop. [26]

Since a male receives his single X-chromosome from his mother, the son of a healthy female silently carrying the deficient gene will have a 50% chance of inheriting that gene from her and with it the disease; and if his mother is affected with haemophilia, he will have a 100% chance of being a haemophiliac. In contrast, for a female to inherit the disease, she must receive two deficient X-chromosomes, one from her mother and the other from her father (who must therefore be a haemophiliac himself). Hence, haemophilia is expressed far more commonly among males than females, while females, who must have two deficient X-chromosomes in order to have haemophilia, are far more likely to be silent carriers, survive childhood and to submit each of her genetic children to an at least 50% risk of receiving the deficient gene. However, it is possible for female carriers to become mild haemophiliacs due to lyonisation (inactivation) of the X-chromosomes. Haemophiliac daughters are more common than they once were, as improved treatments for the disease have allowed more haemophiliac males to survive to adulthood and become parents. Adult females may experience menorrhagia (heavy periods) due to the bleeding tendency. The pattern of inheritance is criss-cross type. This type of pattern is also seen in colour blindness.[ citation needed ]

A mother who is a carrier has a 50% chance of passing the faulty X-chromosome to her daughter, while an affected father will always pass on the affected gene to his daughters. A son cannot inherit the defective gene from his father. Genetic testing and genetic counselling is recommended for families with haemophilia. Prenatal testing, such as amniocentesis, is available to pregnant women who may be carriers of the condition. [27]

As with all genetic disorders, it is also possible for a human to acquire it spontaneously through mutation, rather than inheriting it, because of a new mutation in one of their parents' gametes. Spontaneous mutations account for about 33% of all cases of haemophilia A. [28] About 30% of cases of haemophilia B are the result of a spontaneous gene mutation.

If a female gives birth to a haemophiliac son, either the female is a carrier for the blood disorder or the haemophilia was the result of a spontaneous mutation. [29] Until modern direct DNA testing, however, it was impossible to determine if a female with only healthy children was a carrier or not. [30]

If a male has the disease and has children with a female who is not a carrier, his daughters will be carriers of haemophilia. His sons, however, will not be affected with the disease. The disease is X-linked and the father cannot pass haemophilia through the Y-chromosome. Males with the disorder are then no more likely to pass on the gene to their children than carrier females, though all daughters they sire will be carriers and all sons they father will not have haemophilia (unless the mother is a carrier) [31]

Severity

There are numerous different mutations which cause each type of haemophilia. Due to differences in changes to the genes involved, people with haemophilia often have some level of active clotting factor. Individuals with less than 1% active factor are classified as having severe haemophilia, those with 1–5% active factor have moderate haemophilia, and those with mild haemophilia have between 5% and 40% of normal levels of active clotting factor. [21]

Diagnosis

Haemophilia can be diagnosed before, during or after birth if there is a family history of the condition. Several options are available to parents. If there is no family history of haemophilia, it is usually only diagnosed when a child begins to walk or crawl. Affected children may experience joint bleeds or easy bruising. [32]

Mild haemophilia may only be discovered later, usually after an injury or a dental or surgical procedure.[ citation needed ]

Before pregnancy

Genetic testing and counselling are available to help determine the risk of passing the condition onto a child. [32] This may involve testing a sample of tissue or blood to look for signs of the genetic mutation that causes haemophilia. [32]

During pregnancy

A pregnant woman with a history of haemophilia in her family can test for the haemophilia gene. Such tests include:

There is a small risk of these procedures causing problems such as miscarriage or premature labour, so the woman may discuss this with the doctor in charge of her care. [32]

After birth

If haemophilia is suspected after a child has been born, a blood test can usually confirm the diagnosis. Blood from the umbilical cord can be tested at birth if there's a family history of haemophilia. A blood test will also be able to identify whether a child has haemophilia A or B, and how severe it is. [32]

Classification

There are several types of haemophilia: haemophilia A, haemophilia B, haemophilia C, parahaemophilia, acquired haemophilia A, and acquired haemophilia B. [35] [36] [37] [38]

Haemophilia A is a recessive X-linked genetic disorder resulting in a deficiency of functional clotting Factor VIII. [36] Haemophilia B is also a recessive X-linked genetic disorder involving a lack of functional clotting Factor IX. [39] Haemophilia C is an autosomal genetic disorder involving a lack of functional clotting Factor XI. Haemophilia C is not completely recessive, as heterozygous individuals also show increased bleeding. [37]

The type of haemophilia known as parahaemophilia is a mild and rare form and is due to a deficiency in factor V. This type can be inherited or acquired. [10]

A non-genetic form of haemophilia is caused by autoantibodies against factor VIII and so is known as acquired haemophilia A. [15] It is a rare but potentially life-threatening bleeding disorder caused by the development of autoantibodies (inhibitors) directed against plasma coagulation factors. [40] Acquired haemophilia can be associated with cancers, autoimmune disorders and following childbirth. [41]

Management

There is no long-term cure. Treatment and prevention of bleeding episodes is done primarily by replacing the missing blood clotting factors. [3]

Clotting factors

Commercially produced factor concentrates such as "Advate", a recombinant Factor VIII, come as a white powder in a vial which must be mixed with sterile water prior to intravenous injection. Factor VIII concentrate in Commercial Packaging.JPG
Commercially produced factor concentrates such as "Advate", a recombinant Factor VIII, come as a white powder in a vial which must be mixed with sterile water prior to intravenous injection.

Clotting factors are usually not needed in mild haemophilia. [16] In moderate haemophilia clotting factors are typically only needed when bleeding occurs or to prevent bleeding with certain events. [16] In severe haemophilia preventive use is often recommended two or three times a week and may continue for life. [16] Rapid treatment of bleeding episodes decreases damage to the body. [16]

Factor VIII is used in haemophilia A and factor IX in haemophilia B. Factor replacement can be either isolated from human plasma, recombinant, or a combination of the two. Some people develop antibodies (inhibitors) against the replacement factors given to them, so the amount of the factor has to be increased or non-human replacement products must be given, such as porcine factor VIII. [42]

If a person becomes refractory to replacement coagulation factor as a result of high levels of circulating inhibitors, this may be partially overcome with recombinant human factor VIII. [43]

In early 2008, the US Food and Drug Administration (FDA) approved an anti-haemophilic drug completely free of albumin, which made it the first anti-haemophilic drug in the US to use an entirely synthetic purification process. [44] Since 1993 recombinant factor products (which are typically cultured in Chinese hamster ovary (CHO) tissue culture cells and involve little, if any human plasma products) have been available and have been widely used in wealthier western countries. While recombinant clotting factor products offer higher purity and safety, they are, like concentrate, extremely expensive, and not generally available in the developing world. In many cases, factor products of any sort are difficult to obtain in developing countries.[ citation needed ]

Clotting factors are either given preventively or on-demand. Preventive use involves the infusion of clotting factor on a regular schedule in order to keep clotting levels sufficiently high to prevent spontaneous bleeding episodes. On-demand (or episodic) treatment involves treating bleeding episodes once they arise. In 2007, a trial comparing on-demand treatment of boys (< 30 months) with haemophilia A with prophylactic treatment (infusions of 25 IU/kg body weight of Factor VIII every other day) in respect to its effect on the prevention of joint-diseases. When the boys reached 6 years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group had a normal index joint-structure on MRI. [45] Preventative treatment, however, resulted in average costs of $300,000 per year. The author of an editorial published in the same issue of the NEJM supports the idea that prophylactic treatment not only is more effective than on demand treatment but also suggests that starting after the first serious joint-related haemorrhage may be more cost effective than waiting until the fixed age to begin. [46] Most haemophiliacs in third world countries have limited or no access to commercial blood clotting factor products. [47]

Other

Desmopressin (DDAVP) may be used in those with mild haemophilia A. [16] Tranexamic acid or epsilon aminocaproic acid may be given along with clotting factors to prevent breakdown of clots. [16]

Pain medicines, steroids, and physical therapy may be used to reduce pain and swelling in an affected joint. [16] In those with severe hemophilia A already receiving FVIII, emicizumab may provide some benefit. [48] Different treatments are used to help those with an acquired form of hemophilia in addition to the normal clotting factors. Often the most effective treatment is corticosteroids which remove the auto-antibodies in half of people. As a secondary route of treatment, cyclophosphamide and cyclosporine are used and are proven effective for those who did not respond to the steroid treatments. In rare cases a third route or treatment is used, high doses of intravenous immunoglobulin or immunosorbent that works to help control bleeding instead of battling the auto-antibodies. [49]

Contraindications

Anticoagulants such as heparin and warfarin are contraindicated for people with haemophilia as these can aggravate clotting difficulties. Also contraindicated are those drugs which have "blood thinning" side effects. For instance, medicines which contain aspirin, ibuprofen, or naproxen sodium should not be taken because they are well known to have the side effect of prolonged bleeding. [50]

Also contraindicated are activities with a high likelihood of trauma, such as motorcycling and skateboarding. Popular sports with very high rates of physical contact and injuries such as American football, hockey, boxing, wrestling, and rugby should be avoided by people with haemophilia. [50] [51] Other active sports like soccer, baseball, and basketball also have a high rate of injuries, but have overall less contact and should be undertaken cautiously and only in consultation with a doctor. [50]

Prognosis

Like most aspects of the disorder, life expectancy varies with severity and adequate treatment. People with severe haemophilia who do not receive adequate, modern treatment have greatly shortened lifespans and often do not reach maturity. Prior to the 1960s when effective treatment became available, average life expectancy was only 11 years. [21] By the 1980s the life span of the average haemophiliac receiving appropriate treatment was 50–60 years. [21] Today with appropriate treatment, males with haemophilia typically have a near normal quality of life with an average lifespan approximately 10 years shorter than an unaffected male. [52]

Since the 1980s the primary leading cause of death of people with severe haemophilia has shifted from haemorrhage to HIV/AIDS acquired through treatment with contaminated blood products. [21] The second leading cause of death related to severe haemophilia complications is intracranial haemorrhage which today accounts for one third of all deaths of people with haemophilia. Two other major causes of death include hepatitis infections causing cirrhosis and obstruction of air or blood flow due to soft tissue haemorrhage. [21]

Epidemiology

Haemophilia frequency is about 1 instance in every 10,000 births (or 1 in 5,000 male births) for haemophilia A and 1 in 50,000 births for haemophilia B. [53] About 18,000 people in the United States have haemophilia. Each year in the US, about 400 babies are born with the disorder. Haemophilia usually occurs in males and less often in females. [54] It is estimated that about 2,500 Canadians have haemophilia A, and about 500 Canadians have haemophilia B. [55]

History

"About seventy or eighty years ago, a woman by name of Smith, settled in the vicinity of Plymouth, New Hampshire, and transmitted the following idiosyncrasy to her descendants. It is one, she observed, to which her family is unfortunately subject, and had been the source not only of great solicitude, but frequently the cause of death. If the least scratch is made on the skin of some of them, as mortal a hemorrhagy will eventually ensue as if the largest wound is inflicted. (...) So assured are the members of this family of the terrible consequences of the least wound, that they will not suffer themselves to be bled on any consideration, having lost a relation by not being able to stop the discharge occasioned by this operation."

John C. Otto, 1803 [56]

Scientific discovery

The excessive bleeding was known to ancient people. The Talmud instructs that a boy must not be circumcised if he had two brothers who died due to complications arising from their circumcisions, and Maimonides says that this excluded paternal half-brothers. [57] This may have been due to a concern about hemophilia. [58] The first medical professional to describe the disease was Arab surgeon Al-Zahrawi, also known as Abulcasis. In the tenth century he described families whose males died of bleeding after only minor traumas. [59] While many other such descriptive and practical references to the disease appear throughout historical writings, scientific analysis did not begin until the start of the nineteenth century.[ citation needed ]

In 1803, John Conrad Otto, a Philadelphian physician, wrote an account about "a hemorrhagic disposition existing in certain families" in which he called the affected males "bleeders". [60] He recognised that the disorder was hereditary and that it affected mostly males and was passed down by healthy females. His paper was the second paper to describe important characteristics of an X-linked genetic disorder (the first paper being a description of colour blindness by John Dalton who studied his own family). Otto was able to trace the disease back to a woman who settled near Plymouth, New Hampshire, in 1720. The idea that affected males could pass the trait onto their unaffected daughters was not described until 1813 when John F. Hay, published an account in The New England Journal of Medicine . [61] [62]

In 1924, a Finnish doctor discovered a hereditary bleeding disorder similar to haemophilia localised in Åland, southwest of Finland. [63] This bleeding disorder is called "Von Willebrand Disease".

The term "haemophilia" is derived from the term "haemorrhaphilia" which was used in a description of the condition written by Friedrich Hopff in 1828, while he was a student at the University of Zurich. [60] [64] In 1937, Patek and Taylor, two doctors from Harvard, discovered anti-haemophilic globulin. [65] In 1947, Alfredo Pavlovsky, a doctor from Buenos Aires, found haemophilia A and haemophilia B to be separate diseases by doing a lab test. This test was done by transferring the blood of one haemophiliac to another haemophiliac. The fact that this corrected the clotting problem showed that there was more than one form of haemophilia.[ citation needed ]

European royalty

Haemophilia in European royalty Erbgang Bluterkrankheit.svg
Haemophilia in European royalty

Haemophilia has featured prominently in European royalty and thus is sometimes known as 'the royal disease'. Queen Victoria passed the mutation for haemophilia B [66] [67] to her son Leopold and, through two of her daughters, Alice and Beatrice, to various royals across the continent, including the royal families of Spain, Germany, and Russia. In Russia, Tsarevich Alexei, the son and heir of Tsar Nicholas II, famously had haemophilia, which he had inherited from his mother, Empress Alexandra, one of Queen Victoria's granddaughters. The haemophilia of Alexei would result in the rise to prominence of the Russian mystic Grigori Rasputin, at the imperial court. [68]

It was claimed that Rasputin was successful at treating Tsarevich Alexei's haemophilia. At the time, a common treatment administered by professional doctors was to use aspirin, which worsened rather than lessened the problem. It is believed that, by simply advising against the medical treatment, Rasputin could bring visible and significant improvement to the condition of Tsarevich Alexei. [69]

In Spain, Queen Victoria's youngest daughter, Princess Beatrice, had a daughter Victoria Eugenie of Battenberg, who later became Queen of Spain. Two of her sons were haemophiliacs and both died from minor car accidents. Her eldest son, Prince Alfonso of Spain, Prince of Asturias, died at the age of 31 from internal bleeding after his car hit a telephone booth. [70] Her youngest son, Infante Gonzalo, died at age 19 from abdominal bleeding following a minor car accident in which he and his sister hit a wall while avoiding a cyclist. Neither appeared injured or sought immediate medical care and Gonzalo died two days later from internal bleeding. [71]

Treatment

The method for the production of an antihaemophilic factor was discovered by Judith Graham Pool from Stanford University in 1964, [72] and approved for commercial use in 1971 in the United States under the name Cryoprecipitated AHF . [73] Together with the development of a system for transportation and storage of human plasma in 1965, this was the first time an efficient treatment for haemophilia became available. [74]

Blood contamination

Ryan White was an American haemophiliac who became infected with HIV/AIDS through contaminated blood products. Ryan White.jpg
Ryan White was an American haemophiliac who became infected with HIV/AIDS through contaminated blood products.

Up until late 1985 many people with haemophilia received clotting factor products that posed a risk of HIV and hepatitis C infection. The plasma used to create the products was not screened or tested, nor had most of the products been subject to any form of viral inactivation.[ citation needed ]

Tens of thousands worldwide were infected as a result of contaminated factor products including more than 10,000 people in the United States, [75] 3,500 British, 1,400 Japanese, [76] 700 Canadians, [77] 250 Irish, [78] and 115 Iraqis. [79]

Infection via the tainted factor products had mostly stopped by 1986 by which time viral inactivation methods had largely been put into place, [80] although some products were shown to still be dangerous in 1987. [81]

Research

Gene therapy

In those with severe haemophilia, gene therapy may reduce symptoms to those that a person with mild or moderate haemophilia might have. [17] The best results have been found in haemophilia B. [17] In 2016 early stage human research was ongoing with a few sites recruiting participants. [17] In 2017 a gene therapy trial on nine people with haemophilia A reported that high doses did better than low doses. [82] [83] It is not currently an accepted treatment for haemophilia. [16]

In July 2022 results of a gene therapy candidate for haemophilia B called FLT180 were announced, it works using an adeno-associated virus (AAV) to restore the clotting factor IX (FIX) protein, normal levels of the protein were observed with low doses of the therapy but immunosuppression was necessitated to decrease the risk of vector-related immune responses. [84] [85] [86]

In November 2022, the first gene therapy treatment for Hemophilia B was approved by the U.S. Food and Drug Administration, called Hemgenix. It is a single-dose treatment that gives the patient the genetic information required to produce Factor IX. [87]

In June 2023, the FDA approved the first gene therapy treatment for Hemophilia A, called Roctavian. It was only approved for patients with severe cases, but it has been shown to reduce yearly bleeding episodes by 50%. It works similarly to Hemgenix, being administered by intravenous infusion that contains a gene for Factor VIII. [88]

See also

Related Research Articles

<span class="mw-page-title-main">Haemophilia A</span> Medical condition

Haemophilia A is a blood clotting disorder caused by a genetic deficiency in clotting factor VIII, thereby resulting in significant susceptibility to bleeding, both internally and externally. This condition occurs almost exclusively in males born to carrier mothers due to X-linked recessive inheritance. Nevertheless, rare isolated cases do emerge from de novo (spontaneous) mutations.

<span class="mw-page-title-main">Haemophilia B</span> Genetic X-linked recessive bleeding disorder

Haemophilia B, also spelled hemophilia B, is a blood clotting disorder causing easy bruising and bleeding due to an inherited mutation of the gene for factor IX, and resulting in a deficiency of factor IX. It is less common than factor VIII deficiency.

von Willebrand disease Medical condition

Von Willebrand disease (VWD) is the most common hereditary blood-clotting disorder in humans. An acquired form can sometimes result from other medical conditions. It arises from a deficiency in the quality or quantity of von Willebrand factor (VWF), a multimeric protein that is required for platelet adhesion. It is known to affect several breeds of dogs as well as humans. The three forms of VWD are hereditary, acquired, and pseudo or platelet type. The three types of hereditary VWD are VWD type 1, VWD type 2, and VWD type 3. Type 2 contains various subtypes. Platelet type VWD is also an inherited condition.

<span class="mw-page-title-main">Haemophilia C</span> Medical condition

Haemophilia C (also known as plasma thromboplastin antecedent deficiency or Rosenthal syndrome) is a mild form of haemophilia affecting both sexes, due to factor XI deficiency. It predominantly occurs in Ashkenazi Jews. It is the fourth most common coagulation disorder after von Willebrand's disease and haemophilia A and B. In the United States, it is thought to affect 1 in 100,000 of the adult population, making it 10% as common as haemophilia A.

<span class="mw-page-title-main">Factor VIII</span> Blood-clotting protein

Factor VIII (FVIII) is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene. Defects in this gene result in hemophilia A, an X-linked coagulation disorder. Factor VIII is produced in the liver’s sinusoidal cells and endothelial cells outside the liver throughout the body. This protein circulates in the bloodstream in an inactive form, bound to another molecule called von Willebrand factor, until an injury that damages blood vessels occurs. In response to injury, coagulation factor VIII is activated and separates from von Willebrand factor. The active protein interacts with another coagulation factor called factor IX. This interaction sets off a chain of additional chemical reactions that form a blood clot.

<span class="mw-page-title-main">Bleeding diathesis</span> Medical condition

In medicine (hematology), bleeding diathesis is an unusual susceptibility to bleed (hemorrhage) mostly due to hypocoagulability, in turn caused by a coagulopathy. Therefore, this may result in the reduction of platelets being produced and leads to excessive bleeding. Several types of coagulopathy are distinguished, ranging from mild to lethal. Coagulopathy can be caused by thinning of the skin, such that the skin is weakened and is bruised easily and frequently without any trauma or injury to the body. Also, coagulopathy can be contributed by impaired wound healing or impaired clot formation.

<span class="mw-page-title-main">Coagulation factor VII</span> Mammalian protein found in humans

Coagulation factor VII is one of the proteins that causes blood to clot in the coagulation cascade, and in humans is coded for by the gene F7. It is an enzyme of the serine protease class. Once bound to tissue factor released from damaged tissues, it is converted to factor VIIa, which in turn activates factor IX and factor X.

<span class="mw-page-title-main">X-linked recessive inheritance</span> Mode of inheritance

X-linked recessive inheritance is a mode of inheritance in which a mutation in a gene on the X chromosome causes the phenotype to be always expressed in males and in females who are homozygous for the gene mutation, see zygosity. Females with one copy of the mutated gene are carriers.

<span class="mw-page-title-main">Coagulopathy</span> Condition involving impaired blood clotting ability

Coagulopathy is a condition in which the blood's ability to coagulate is impaired. This condition can cause a tendency toward prolonged or excessive bleeding, which may occur spontaneously or following an injury or medical and dental procedures.

Congenital afibrinogenemia is a rare, genetically inherited blood fibrinogen disorder in which the blood does not clot normally due to the lack of fibrinogen, a blood protein necessary for coagulation. This disorder is autosomal recessive, meaning that two unaffected parents can have a child with the disorder. The lack of fibrinogen expresses itself with excessive and, at times, uncontrollable bleeding.

<span class="mw-page-title-main">Factor VII deficiency</span> Medical condition

Factor VII deficiency is a bleeding disorder characterized by a lack in the production of Factor VII (FVII) (proconvertin), a protein that causes blood to clot in the coagulation cascade. After a trauma factor VII initiates the process of coagulation in conjunction with tissue factor in the extrinsic pathway.

<span class="mw-page-title-main">Haemophilia in European royalty</span> Preponderance of a genetic disorder throughout European royalty

Haemophilia figured prominently in the history of European royalty in the 19th and 20th centuries. Queen Victoria and her husband, Prince Albert, of the United Kingdom, through two of their five daughters – Princess Alice and Princess Beatrice – passed the mutation to various royal houses across the continent, including the royal families of Spain, Germany, and Russia. Victoria's youngest son, Prince Leopold, Duke of Albany, also had the disease, though none of her three elder sons did. Tests on the remains of the Romanov imperial family show that the specific form of haemophilia passed down by Queen Victoria was probably the relatively rare haemophilia B. The presence of haemophilia B within the European royal families was well-known, with the condition once popularly known as "the royal disease".

An obligate carrier is an individual who may be clinically unaffected but who must carry a gene mutation based on analysis of the family history; usually applies to disorders inherited in an autosomal recessive and X-linked recessive manner.

Recombinant factor VIIa (rfVIIa) is a form of blood factor VII that has been manufactured via recombinant technology. It is administered via an injection into a vein. It is used to treat bleeding episodes in people who have acquired haemophilia, among other indications. There are several disimilar forms, and biosimilars for each. All forms are activated.

<span class="mw-page-title-main">Jeanne Lusher</span> American physician

Jeanne Marie Lusher, M.D. was an American physician, pediatric hematologist/oncologist, and a researcher in the field of bleeding disorders of childhood, and has served as the director of Hemostasis Program at the Children's Hospital of Michigan until her retirement on June 28, 2013.

<span class="mw-page-title-main">Factor I deficiency</span> Medical condition

Factor I deficiency, also known as fibrinogen deficiency, is a rare inherited bleeding disorder related to fibrinogen function in the blood coagulation cascade. It is typically subclassified into four distinct fibrinogen disorders: afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia.

<span class="mw-page-title-main">X-linked thrombocytopenia</span> Medical condition

X-linked thrombocytopenia, also referred to as XLT or thrombocytopenia 1, is an inherited clotting disorder that primarily affects males. It is a WAS-related disorder, meaning it is caused by a mutation in the Wiskott–Aldrich syndrome (WAS) gene, which is located on the short arm of the X chromosome. WAS-related disorders include Wiskott–Aldrich syndrome, XLT, and X-linked congenital neutropenia (XLN). Of the WAS-related disorders, X-linked thrombocytopenia is considered to be the milder phenotype. Between 1 and 10 per million males worldwide are affected with this disorder. Females may be affected with this disorder but this is very rare since females have two X chromosomes and are therefore typically carriers of the mutation.

Factor XII deficiency is a deficiency in the production of factor XII (FXII), a plasma glycoprotein and clotting factor that participates in the coagulation cascade and activates factor XI. FXII appears to be not essential for blood clotting, as individuals with this condition are usually asymptomatic and form blood clots in vivo. FXII deficiency tends to be identified during presurgical laboratory screening for bleeding disorders.

Congenital hypofibrinogenemia is a rare disorder in which one of the three genes responsible for producing fibrinogen, a critical blood clotting factor, is unable to make a functional fibrinogen glycoprotein because of an inherited mutation. In consequence, liver cells, the normal site of fibrinogen production, make small amounts of this critical coagulation protein, blood levels of fibrinogen are low, and individuals with the disorder may develop a coagulopathy, i.e. a diathesis or propensity to experience episodes of abnormal bleeding. However, individuals with congenital hypofibrinogenemia may also have episodes of abnormal blood clot formation, i.e. thrombosis. This seemingly paradoxical propensity to develop thrombosis in a disorder causing a decrease in a critical protein for blood clotting may be due to the function of fibrin to promote the lysis or disintegration of blood clots. Lower levels of fibrin may reduce the lysis of early fibrin strand depositions and thereby allow these depositions to develop into clots.

Etranacogene dezaparvovec, sold under the brand name Hemgenix is a gene therapy used for the treatment of hemophilia B. Etranacogene dezaparvovec is an adeno-associated virus vector-based gene therapy which consists of a viral vector carrying a gene for clotting Factor IX. The gene is expressed in the liver to produce Factor IX protein, to increase blood levels of Factor IX and thereby limit bleeding episodes. Hemophilia B is a genetic bleeding disorder resulting from missing or insufficient levels of blood clotting Factor IX, a protein needed to produce blood clots to stop bleeding.

References

  1. 1 2 3 4 "What Are the Signs and Symptoms of Hemophilia?". NHLBI. July 13, 2013. Archived from the original on 17 September 2016. Retrieved 8 September 2016.
  2. 1 2 3 4 5 6 "What Is Hemophilia?". NHLBI. July 13, 2013. Archived from the original on 4 October 2016. Retrieved 8 September 2016.
  3. 1 2 3 4 5 6 7 "Hemophilia Facts". CDC. August 26, 2014. Archived from the original on 27 August 2016. Retrieved 8 September 2016.
  4. 1 2 3 4 "How Is Hemophilia Diagnosed?". NHLBI. July 13, 2013. Archived from the original on 15 September 2016. Retrieved 10 September 2016.
  5. 1 2 3 4 5 Wynbrandt J, Ludman MD (1 January 2009). The Encyclopedia of Genetic Disorders and Birth Defects. Infobase Publishing. p. 194. ISBN   978-1-4381-2095-9. Archived from the original on 8 January 2014. Retrieved 25 August 2013.
  6. "What Is Hemophilia?". cdc.gov. U.S. Centers for Disease Control. 12 May 2020. Retrieved 3 April 2021.
  7. Douglas Harper. "Online Etymology Dictionary". Archived from the original on 6 March 2008. Retrieved 10 October 2007.
  8. 1 2 3 4 "What Causes Hemophilia?". NHLBI. July 13, 2013. Archived from the original on 8 September 2016. Retrieved 10 September 2016.
  9. Franchini M, Mannucci PM (October 2011). "Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice". British Journal of Clinical Pharmacology. 72 (4): 553–62. doi:10.1111/j.1365-2125.2010.03899.x. PMC   3195733 . PMID   21204915.
  10. 1 2 Thalji N, Camire RM (September 2013). "Parahemophilia: new insights into factor v deficiency". Seminars in Thrombosis and Hemostasis. 39 (6): 607–12. doi:10.1055/s-0033-1349224. PMID   23893775. S2CID   21053684.
  11. Camire RM (2012-01-01). "Bioengineered factor Xa as a potential new strategy for hemophilia therapy". Expert Review of Hematology. 5 (2): 121–123. doi:10.1586/ehm.12.13. ISSN   1747-4086. PMID   22475278. S2CID   7065701.
  12. Al-Fadhil N, Pathare A, Ganesh A (2001-10-01). "Traumatic Hyphema and Factor XI Deficiency (Hemophilia C)". Archives of Ophthalmology. 119 (10): 1546–1547. ISSN   0003-9950. PMID   11594962.
  13. Chaudhry R, Usama SM, Babiker HM (2022), "Physiology, Coagulation Pathways", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID   29489185 , retrieved 2022-11-13
  14. Franchini M, Mannucci PM (December 2013). "Acquired haemophilia A: a 2013 update". Thrombosis and Haemostasis. 110 (6): 1114–20. CiteSeerX   10.1.1.684.7962 . doi:10.1160/TH13-05-0363. PMID   24008306. S2CID   2174637.
  15. 1 2 Mulliez SM, Vantilborgh A, Devreese KM (June 2014). "Acquired hemophilia: a case report and review of the literature". International Journal of Laboratory Hematology. 36 (3): 398–407. doi: 10.1111/ijlh.12210 . PMID   24750687. S2CID   205194015.
  16. 1 2 3 4 5 6 7 8 9 10 11 "How Is Hemophilia Treated?". NHLBI. July 13, 2013. Archived from the original on 17 September 2016. Retrieved 10 September 2016.
  17. 1 2 3 4 Peyvandi F, Garagiola I, Young G (9 July 2016). "The past and future of haemophilia: diagnosis, treatments, and its complications". Lancet. 388 (10040): 187–97. doi:10.1016/s0140-6736(15)01123-x. PMID   26897598. S2CID   21945676.
  18. Types of Bleeds Archived 2010-02-13 at the Wayback Machine National Hemophilia Foundation.
  19. Key facts: what is haemophilia? Archived 2009-05-23 at the Wayback Machine The Haemophilia Society.
  20. Benson G, Auerswald G, Dolan G, Duffy A, Hermans C, Ljung R, Morfini M, Šalek SZ (November 2018). "Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management". Blood Transfusion. 16 (6). Blood Transfus.: 535–544. doi:10.2450/2017.0150-17. PMC   6214819 . PMID   29328905.
  21. 1 2 3 4 5 6 7 Hemophilia Overview Archived 2009-09-27 at the Wayback Machine eMedicine from webMD. Dimitrios P Agaliotis, MD, PhD, FACP, Robert A Zaiden, MD, Fellow, and Saduman Ozturk, PA-C. Updated: 24 November 2009.
  22. Medical News Today
  23. Hemophilia Complications Archived 2010-01-21 at the Wayback Machine Mayo Clinic Staff. 16 May 2009
  24. Rodriguez-Merchan EC (2010). "Musculoskeletal Complications of Hemophilia". HSS J. 6 (1): 37–42. doi:10.1007/s11420-009-9140-9. PMC   2821487 . PMID   19921342.
  25. Valentino LA, Hakobyan N, Rodriguez N, Hoots WK (November 2007). "Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage". Haemophilia. 13 (Suppl 3): 10–3. doi:10.1111/j.1365-2516.2007.01534.x. PMID   17822515. S2CID   35723479.
  26. "Hemophilia". Genome.gov. Retrieved 2022-01-21.
  27. Naqvi E. "Hemophilia and Pregnancy – Hemophilia News Today" . Retrieved 2021-10-02.
  28. Kumar P, Clark M (2009). Kumar & Clark's Clinical Medicine (7th ed.). Saunders Elsevier. ISBN   978-0-7020-2993-6.
  29. CDC (2019-04-19). "Information for Women | Hemophilia | NCBDDD | CDC". Centers for Disease Control and Prevention. Retrieved 2022-05-16.
  30. Oldenburg J, Pezeshkpoor B, Pavlova A (November 2014). "Historical review on genetic analysis in hemophilia A". Seminars in Thrombosis and Hemostasis. 40 (8): 895–902. doi:10.1055/s-0034-1395161. ISSN   1098-9064. PMID   25377322. S2CID   23864314.
  31. CDC (2022-08-01). "How Hemophilia is Inherited | Hemophilia | NCBDDD | CDC". Centers for Disease Control and Prevention. Retrieved 2022-12-19.
  32. 1 2 3 4 5 Choices N. "Haemophilia – Diagnosis – NHS Choices". www.nhs.uk. Archived from the original on 2017-01-01. Retrieved 2017-01-01.
  33. "Chorionic villus sampling". National Health Service. 20 July 2018. Retrieved 10 February 2020.
  34. "Amniocentesis". National Health Service. 17 April 2019. Retrieved 10 February 2020.
  35. "What Is Hemophilia? – NHLBI, NIH". www.nhlbi.nih.gov. Archived from the original on 2 July 2016. Retrieved 21 June 2016.
  36. 1 2 "Hemophilia A: MedlinePlus Medical Encyclopedia". www.nlm.nih.gov. Archived from the original on 2016-07-05. Retrieved 2016-06-21.
  37. 1 2 Prasad Mathew, MBBS, DCH, eMedicine – Hemophilia C Archived 2008-12-02 at the Wayback Machine
  38. Páramo L, Enciso Olivera LJ, Noreña I, Amaya MA, Santacruz JC (2019-03-05). "First Case of Acquired Hemophilia B in a Patient with HIV Infection: Case Report and Literature Review". Cureus. 11 (3): e4179. doi: 10.7759/cureus.4179 . ISSN   2168-8184. PMC   6504016 . PMID   31106079.
  39. "Hemophilia B: MedlinePlus Medical Encyclopedia". www.nlm.nih.gov. Archived from the original on 2016-07-05. Retrieved 2016-06-21.
  40. Tribuzi, Susanna, Naccarato, Alessia, Pelagalli, Lorella, et al. Acquired Hemophilia A After Hepatic Yttrium-90 Radioembolization: A Case Report. A&A Case Reports. 2017;9(12):344–345. doi:10.1213/XAA.0000000000000611.
  41. Franchini M, Mannucci PM (December 2013). "Acquired haemophilia A: a 2013 update". Thrombosis and Haemostasis. 110 (6): 1114–20. CiteSeerX   10.1.1.684.7962 . doi:10.1160/TH13-05-0363. PMID   24008306. S2CID   2174637.
  42. Mannucci PM, Franchini M (2017). "Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies". Blood Transfusion. 15 (4): 365–368. doi:10.2450/2016.0030-16. ISSN   1723-2007. PMC   5490733 . PMID   27483484.
  43. Witmer C, Young G (2013). "Factor VIII inhibitors in hemophilia A: rationale and latest evidence". Therapeutic Advances in Hematology. 4 (1): 59–72. doi:10.1177/2040620712464509. ISSN   2040-6207. PMC   3629762 . PMID   23610614.
  44. "FDA Gives the Go-Ahead to Wyeth for Hemophilia A Therapy and Abbott for JIA Drug". GEN – Genetic Engineering and Biotechnology News. 2008-02-22. Retrieved 2021-02-10.
  45. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL (2007). "Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia". N. Engl. J. Med. 357 (6): 535–544. doi: 10.1056/NEJMoa067659 . PMID   17687129.
  46. Roosendaal G, Lafeber F (2007). "Prophylactic treatment for prevention of joint disease in hemophilia—cost versus benefit". N. Engl. J. Med. 357 (6): 603–605. doi:10.1056/NEJMe078098. PMID   17687136.
  47. "Data Collection - WFH Annual Global Survey - World Federation of Hemophilia". www.wfh.org. Archived from the original on 2019-07-25. Retrieved 2018-12-10.
  48. Research Cf. "Approved Drugs – FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors". www.fda.gov. Retrieved 2018-12-10.
  49. Boggio LN, Green D (2001). "Acquired Hemophilia". Reviews in Clinical and Experimental Hematology. 5 (4): 389–404. doi:10.1046/j.1468-0734.2001.00049.x. ISSN   1468-0734. PMID   11844135.
  50. 1 2 3 How to Deal with Hemophilia Archived 2007-02-14 at the Wayback Machine Reviewed by: Larissa Hirsch, MD 2007. kidshealth.org by Nemours. Retrieved 23 January 2010.
  51. "Playing it Safe: Bleeding Disorders, Sports and Exercise Archived 2010-09-14 at the Wayback Machine ". Booklet. National Hemophilia Foundation.
  52. World Federation of Hemophilia Archived 2014-02-01 at the Wayback Machine Frequently Asked Questions. 2005
  53. World Federation of Hemophilia Frequently Asked Questions About Hemophilia Archived 2008-06-12 at the Wayback Machine
  54. "U.S. National Library of Medicine". Archived from the original on 12 October 2007. Retrieved 2 December 2007.
  55. Canadian Hemophilia Society FAQ Archived 2008-02-13 at the Wayback Machine
  56. "Otto JC. The Medical Repository. 1803; Vol VI (1): 1–4". Genmedhist.info. Archived from the original on 2014-09-04. Retrieved 2013-11-21.
  57. Mishne Torah, laws of circumcision, chapter 1 law 18. It explicitly talks about multiple boys who have the same mother, regardless of whether or not they also have the same father.
  58. Singer, Isidore; et al., eds. (1901–1906). "Morbidity". The Jewish Encyclopedia. New York: Funk & Wagnalls.
  59. "Case of the Week 175". University of Utah Medical Library. Archived from the original on 19 May 2011.
  60. 1 2 Nilsson IM (1994). "Haemophilia—then and now". Sydsvenska Medicinhistoriska Sallskapets Arsskrift. 31: 33–52. PMID   11640407.
  61. DIGITISED EARLY PAPERS AND BOOKS ON HUMAN AND MEDICAL GENETICS Archived 2011-07-21 at the Wayback Machine Genetics and Medicine Historical Network, Cardiff University.
  62. Hay J (July 1813). "Account of a remarkable hæmorrhagic disposition, existing in many individuals of the same family". N Engl J Med Surg. 2 (3): 221–5. doi:10.1056/NEJM181307010020302. PMC   5581570 . PMID   30493599.
  63. "Haemophilia Special Issue: von Willebrand's Disease: a Report from a Meeting in the Åland Islands". Haemophilia. 18. 2012. doi:10.1111/hae.2012.18.issue-s6.
  64. "The History of hemophilia". Archived from the original on 31 March 2009. Retrieved 5 June 2009.
  65. Chapter 38 Coagulation Factors V and VIII by GC White and GE Gilbert Archived 2017-09-11 at the Wayback Machine in Blood: principles and practice of hematology: 2nd edition. 2003. Eds. Robert I. Handin, Samuel E. Lux, Thomas P. Stossel. ISBN   978-0-7817-1993-3.
  66. Michael Price (8 October 2009). "Case Closed: Famous Royals Suffered From Hemophilia". ScienceNOW Daily News. AAAS. Archived from the original on 12 October 2009. Retrieved 9 October 2009.
  67. Evgeny I. Rogaev, et al. (8 October 2009). "Genotype Analysis Identifies the Cause of the 'Royal Disease'". Science. 326 (5954): 817. Bibcode:2009Sci...326..817R. doi: 10.1126/science.1180660 . PMID   19815722. S2CID   206522975.
  68. Massie RK (2011). Nicholas and Alexandra: The Classic Account of the Fall of the Romanov Dynasty. Random House. p. 532. ISBN   978-0-307-78847-4.
  69. Jeffreys D (2008). Aspirin: The Remarkable Story of a Wonder Drug. Bloomsbury Publishing. p. 121. ISBN   978-1-59691-816-0.
  70. "Tragic Drama Under the Miami Moon". www.biscaynetimes.com. Archived from the original on 2020-06-25. Retrieved 2020-06-24.
  71. "AUTO CRASH FATAL TO SPANISH PRINCE; Don Gonzalo, 19, Succumbs to Hemophilia After Collision in Austrian Village. INFANTA BEATRIZ DRIVING Swerved Car to Avoid Hitting Bicyclist – Ex-King Present at Son's Bedside". The New York Times. Retrieved 2020-06-24.
  72. Pool JG, Hershgold EJ, Pappenhagen AR (July 1964). "High-potency Antihæmophilic Factor Concentrate prepared from Cryoglobulin Precipitate". Nature. 203 (4942): 312. Bibcode:1964Natur.203..312P. doi: 10.1038/203312a0 . ISSN   0028-0836. PMID   14201780. S2CID   4243913.
  73. "Alphabetical List of Licensed Establishments Including Product Approval Dates as of 30-APR-2019". FDA.
  74. Pool JG, Shannon AE (1965-12-30). "Production of High-Potency Concentrates of Antihemophilic Globulin in a Closed-Bag System: Assay in Vitro and in Vivo". New England Journal of Medicine. 273 (27): 1443–1447. doi:10.1056/NEJM196512302732701. ISSN   0028-4793. PMID   5852902.
  75. White GC (2010). "Hemophilia: an amazing 35-year journey from the depths of HIV to the threshold of cure". Trans. Am. Clin. Climatol. Assoc. 121: 61–73, discussion 74–5. PMC   2917149 . PMID   20697550.
  76. "Japan's Response to the Spread of HIV/AIDS" (PDF). Japan Center for International Exchange. 2004.
  77. "Commemoration of the Tainted Blood Tragedy – Canadian Hemophilia Society". www.hemophilia.ca. 17 October 2017.
  78. "Report of the Tribunal of Inquiry into the Infection with HIV and Hepatitis C of Persons with Haemophilia and Related Matters | Department of Health". health.gov.ie. 30 September 2002.
  79. Zielbauer Pv (4 September 2006). "Iraqis Infected by H.I.V.-Tainted Blood Try New Tool: A Lawsuit". The New York Times.
  80. Lowe GD (August 1987). "Haemophilia, blood products and HIV infection". Scott Med J. 32 (4): 109–11. doi:10.1177/003693308703200404. PMID   3672104. S2CID   21773694.
  81. Picard A. "RCMP lay 32 charges in tainted-blood case". The Globe and Mail.
  82. Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, Yu H, Vettermann C, Pierce GF, Wong WY, Pasi KJ (December 2017). "AAV5-Factor VIII Gene Transfer in Severe Hemophilia A". N. Engl. J. Med. 377 (26): 2519–2530. doi: 10.1056/NEJMoa1708483 . hdl: 10044/1/57163 . PMID   29224506.
  83. van den Berg HM (December 2017). "A Cure for Hemophilia within Reach". N. Engl. J. Med. 377 (26): 2592–2593. doi:10.1056/NEJMe1713888. PMID   29224412.
  84. Chowdary P, Shapiro S, Makris M, Evans G, Boyce S, Talks K, Dolan G, Reiss U, Phillips M, Riddell A, Peralta MR (2022-07-21). "Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B". New England Journal of Medicine. 387 (3): 237–247. doi: 10.1056/NEJMoa2119913 . ISSN   0028-4793. PMID   35857660. S2CID   250697905.
  85. "Novel gene therapy could reduce bleeding risk for haemophilia patients". ScienceDaily. Retrieved 2022-08-03.
  86. "Transformational therapy cures haemophilia B". BBC News. 2022-07-21. Retrieved 2022-08-03.
  87. "HEMGENIX". U.S. Food and Drug Administration. 4 January 2023. Retrieved 17 March 2024.
  88. "FDA Approves First Gene Therapy for Adults with Severe Hemophilia A". U.S. Food and Drug Administration. 30 June 2023. Retrieved 16 March 2024.